Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Dendritic Cell Vaccine against Glioblastoma Multiforme Patients

OTHER RELATED OMICS DATASETS IN: E-GEOD-11100

PROVIDER: PRJNA106981 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Genome and transcriptome study of the response to irinotecan and bevacizumab in recurrent glioblastomas (CIT - Homo sapiens - BEVA)

Project description:A Cartes d'Identite des Tumeurs (CIT) project from the French National League Against Cancer (http://cit.ligue-cancer.net ) 25 glioblastoma multiforme tumors hybridized on Illumina SNP and Affymetrix gene expression arrays. Project leader : François DUCRAY (francois.ducray@chu-lyon.fr). CIT Analysis : Julien LAFFAIRE (laffairej@ligue-cancer.net). Note: PFS : progression-free survival, OS: Overall Survival,BCNU : Carmustine (chemotherapy agent). RESPONDER: if the patient has shown or not shown a response to the treatment (Bevacizumab (Avastin) plus Irinotecan). Progression during : If the disease has progressed (cancer relapse or patient's death); otherwise (patient is alive without relapse).

2013-01-15 | E-MTAB-951 | biostudies-arrayexpress

Transcription profiling of human glioblastoma multiforme tumors taken before dendritic cell vaccination, recurrent tumors after vaccination and control GBM tumors

Project description:Human Glioblastoma Multiforme tumors taken before dendritic cell vaccination, the recurrent tumors taken after vaccination and control GBM tumors from non vaccinated patients. Experiment Overall Design: Six Glioblastoma Multiforme patients underwent surgery. Their brain tumors were removed and analyzed via microarray. The lysate from the tumors were cultured with the patients' dendritic cells and the DCs were injected back into the patients. The patients GBMs returned and they underwent surgery a second time and those tumors were also analyzed via microarray. Tumors from the first and second GBM surgeries of 5 patients who did not receive DC vaccines are included as controls.

2009-04-11 | E-GEOD-11100 | biostudies-arrayexpress

Dendritic Cell Vaccine against Glioblastoma Multiforme Patients

2009-04-03 | GSE11100 | GEO

Adherent and Spheroid Glioblastoma Proteomics

Project description:Dendritic cell (DC)-based immunotherapy against glioblastoma multiforme is a novel treatment hope. Glioblastoma stem-like cells are, however, potentially causing immunoresistance. Glioblastoma cells cultured as gliomaspheres show a stem-like phenotype as opposed to classical adherent culture. They are thus a promising antigen source to specifically target glioblastoma stem-like cells via DC therapy and so overcome immunoresistance. Here we study the importance of gliomasphere-specific. Methodologically, we used 7 gliomaspheres, 3 of them patient-derived, as model system. Gliomasphere-specific protein expression was explored via quantitative proteomics.

2019-04-15 | PXD008244 | Pride

Homo sapiens

Project description:EXPRESSION OF VAV1 IN GLIOBLASTOMA MULTIFORME

| PRJNA130241 | ENA

Homo sapiens

Project description:Copy number analysis of human glioblastoma multiforme

| PRJNA112561 | ENA

Homo sapiens

Project description:DZNep-treated glioblastoma multiforme cancer stem cells

| PRJNA119483 | ENA

Homo sapiens

Project description:RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls

| PRJNA130213 | ENA

B-Cell-based Therapy Controls Glioblastoma Growth by Producing Antibodies that Inhibit Tumor Invasion and Migration

Project description:Glioblastoma multiforme (GBM) is a highly aggressive and malignant brain tumor with limited therapeutic options and poor prognosis. Despite current treatments, the invasive nature of GBM often leads to recurrence. A promising alternative strategy is to harness the immune system's potential against tumor cells. Our previous data showed a B-cell-based vaccine, BVax, can provide a promising therapeutic potential for GBM. In this study, we aim to characterize the antigenic reactivity of BVax-derived antibodies and evaluate their therapeutic potential. We performed immunoproteomics and functional assays in murine models and human GBM patient samples.

2024-09-10 | PXD046712 | Pride

Epigenomic profiling of patient-derived GBM cell lines obtained from GBM patient surgical samples (HGCC resource)

Project description:The recent incorporation of molecular features into the diagnosis of Glioblastoma Multiforme patients has led to an improved categorisation into different tumour subtypes with different prognosis and disease management. In this work, we have exploited the benefits of genome-wide multiomic approaches to identify potential molecular vulnerabilities existing on GBM patients. We used the Illumina MethylationEPIC Beadchip platform to describe the genome-wide 5mC and 5hmC DNA methylation landscape of a total of 9 patient-derived Glioblastoma Multiforme Cell lines obtained from the human glioblastoma cell culture resource (HGCC) and 4 brain samples obtained from non-tumoral controls

2023-06-01 | E-MTAB-12473 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data